190 related articles for article (PubMed ID: 22426807)
1. Interleukin-4 and CpG oligonucleotide therapy suppresses the outgrowth of tumors by activating tumor-specific Th1-type immune responses.
Kajiwara A; Doi H; Eguchi J; Ishii S; Hiraide-Sasagawa A; Sakaki M; Omori R; Hiroishi K; Imawari M
Oncol Rep; 2012 Jun; 27(6):1765-71. PubMed ID: 22426807
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-alpha transduction.
Eguchi J; Hiroishi K; Ishii S; Baba T; Matsumura T; Hiraide A; Okada H; Imawari M
Gene Ther; 2005 May; 12(9):733-41. PubMed ID: 15772692
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
Ishii S; Hiroishi K; Eguchi J; Hiraide A; Imawari M
Gene Ther; 2006 Jan; 13(1):78-87. PubMed ID: 16107857
[TBL] [Abstract][Full Text] [Related]
4. Cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-alpha-expressing tumor cells effectively induce dendritic cell maturation in vitro.
Hiraide A; Hiroishi K; Ishii S; Eguchi J; Imawari M
Anticancer Res; 2006; 26(1A):211-8. PubMed ID: 16475701
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells stimulated with cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-alpha-expressing tumor cells effectively reduce outgrowth of established tumors in vivo.
Hiraide A; Hiroishi K; Eguchi J; Ishii S; Doi H; Imawari M
Cancer Sci; 2008 Aug; 99(8):1663-9. PubMed ID: 18754881
[TBL] [Abstract][Full Text] [Related]
6. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
[TBL] [Abstract][Full Text] [Related]
8. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
Heckelsmiller K; Beck S; Rall K; Sipos B; Schlamp A; Tuma E; Rothenfusser S; Endres S; Hartmann G
Eur J Immunol; 2002 Nov; 32(11):3235-45. PubMed ID: 12555669
[TBL] [Abstract][Full Text] [Related]
9. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
Jakob T; Walker PS; Krieg AM; Udey MC; Vogel JC
J Immunol; 1998 Sep; 161(6):3042-9. PubMed ID: 9743369
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Hiroishi K; Tüting T; Tahara H; Lotze MT
Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
12. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
[TBL] [Abstract][Full Text] [Related]
13. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
14. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
15. Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides.
Paget C; Bialecki E; Fontaine J; Vendeville C; Mallevaey T; Faveeuw C; Trottein F
J Immunol; 2009 Feb; 182(4):1846-53. PubMed ID: 19201836
[TBL] [Abstract][Full Text] [Related]
16. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
17. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
18. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis.
Zimmermann S; Egeter O; Hausmann S; Lipford GB; Röcken M; Wagner H; Heeg K
J Immunol; 1998 Apr; 160(8):3627-30. PubMed ID: 9558060
[TBL] [Abstract][Full Text] [Related]
20. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
Liu Y; Luo X; Yang C; Yu S; Xu H
Vaccine; 2011 Aug; 29(34):5778-84. PubMed ID: 21664398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
